Record-Breaking Price Movement
On 01 Jun 2026, Venus Remedies Ltd’s stock price surged to Rs. 1,346.95, marking a new 52-week and all-time high. The stock opened with a 5.00% gain and maintained this level throughout the trading session, outperforming its sector by 4.59%. This price movement was part of a six-day consecutive gain streak, during which the stock appreciated by 30.59%, underscoring strong momentum in the market.
The stock’s performance on this day also significantly outpaced the broader market, with the Sensex registering a modest 0.33% increase. Over the past week, Venus Remedies Ltd has delivered an 18.46% return compared to the Sensex’s decline of 1.91%, while its one-month gain stands at 39.08% against the Sensex’s 2.45% fall.
Long-Term Outperformance
Venus Remedies Ltd’s stock has demonstrated remarkable resilience and growth over extended periods. The company’s three-month return of 100.39% starkly contrasts with the Sensex’s 7.70% decline. Over the past year, the stock has surged by 207.24%, while the Sensex has fallen by 7.89%. Year-to-date, the stock has gained 75.61%, outperforming the Sensex’s 11.96% drop.
Looking further back, the company has delivered a 458.32% return over three years and 325.98% over five years, both significantly exceeding the Sensex’s respective gains of 20.18% and 44.46%. Over a decade, Venus Remedies Ltd’s stock has appreciated by an extraordinary 1,591.09%, compared to the Sensex’s 180.85% rise.
Technical Strength and Market Position
The stock’s technical indicators reflect a bullish trend that began on 12 Mar 2026 at a price of Rs. 927.50. Venus Remedies Ltd is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling strong upward momentum. Key technical indicators such as MACD, Bollinger Bands, KST, Dow Theory, and On-Balance Volume (OBV) all show bullish signals on both weekly and monthly timeframes.
Immediate support is established at Rs. 417.65, the 52-week low, while the stock has surpassed major resistance levels at Rs. 707.12 (200 DMA), Rs. 863.19 (100 DMA), and Rs. 1,020.28 (20 DMA), culminating in the current all-time high.
Financial Performance and Quality Metrics
Venus Remedies Ltd’s financial results underpin its stock price appreciation. The company reported its highest quarterly net sales at Rs. 259.40 crores and a record quarterly PBDIT of Rs. 63.42 crores. Operating profit has grown at an annual rate of 45.72%, while net profit surged by 126.19% in the latest quarter ending March 2026. The company has declared positive results for six consecutive quarters, reflecting consistent operational strength.
Return on Capital Employed (ROCE) reached a high of 19.85% in the half-year period, while Return on Equity (ROE) stands at a healthy 15.5%. The company maintains a net-debt-free status, supported by a strong balance sheet and excellent capital structure. Interest coverage remains robust at 50.94 times, and the company has zero promoter share pledging, further reinforcing financial stability.
Valuation and Market Capitalisation
Venus Remedies Ltd is classified as a micro-cap company with a market capitalisation grade reflecting this status. The stock trades at a price-to-earnings (P/E) ratio of 17 times and a price-to-book value (P/BV) of 2.58 times. Its enterprise value to EBITDA ratio stands at 11.03 times, while the PEG ratio is notably low at 0.10, indicating attractive valuation relative to earnings growth.
The stock’s dividend yield is not available, but it declared a latest dividend of Rs. 3 per share. The ex-dividend date was 23 Sep 2013, with no recent payout ratio data disclosed.
Institutional Participation and Market Sentiment
Institutional investors have increased their stake by 0.72% over the previous quarter, collectively holding 4% of the company’s shares. This growing institutional interest reflects confidence in the company’s fundamentals and long-term prospects. Delivery volumes have also shown an upward trend, with a 31.81% increase in one-day delivery volume compared to the five-day average, indicating active trading interest.
Quality Assessment and Growth Indicators
The company’s overall quality grade is assessed as average, with good growth and excellent capital structure. Five-year sales growth is recorded at 7.02%, while EBIT growth over the same period is a robust 45.72%. The company operates with low debt, reflected in an average debt to EBITDA ratio of 0.54 and a net cash position with net debt to equity at -0.14.
Tax ratio stands at 23.37%, and the company maintains a zero dividend payout ratio, indicating reinvestment of earnings into growth initiatives. The absence of pledged shares and strong interest coverage further highlight the company’s financial discipline.
Summary of Key Financial and Market Metrics
• All-time high stock price: Rs. 1,346.95 (01 Jun 2026)
• Six consecutive days of gains, with a 30.59% return in this period
• One-year return of 207.24%, vastly outperforming the Sensex
• Highest quarterly net sales and PBDIT recorded in latest results
• Net-debt-free status with strong interest coverage
• Institutional holdings increased to 4%
• Trading above all major moving averages with bullish technical indicators
Venus Remedies Ltd’s achievement of an all-time high price is a testament to its sustained financial performance, operational strength, and favourable market positioning within the Pharmaceuticals & Biotechnology sector. The company’s consistent growth in profitability, strong balance sheet, and positive technical signals have collectively contributed to this milestone.
